First-Line Afatinib plus Cetuximab for <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study - Concepedia

Concepedia

Publication | Open Access

First-Line Afatinib plus Cetuximab for <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study

DOI Full Paper Access

20

Citations

26

References

2021

Year

Alexis B. Cortot, Anne Madroszyk, Etienne Giroux‐Leprieur, Olivier Molinier, Élisabeth Quoix, H. Bérard, Josiane Otto, Isabelle Rault, Denis Moro‐Sibilot, Judith Raimbourg,

Clinical Cancer Research

Abstract

These results suggest that addition of cetuximab to afatinib does not warrant further investigation in treatment-naïve advanced <i>EGFR</i>-mutant NSCLC.

References

	Year	Citations

Page 1